Chemokine (c-c motif) ligand 2 (ccl2) in sera of patients with type 1 diabetes and diabetic complications

Ruili Guan, Sharad B Purohit, Hongjie Wang, Bruce Bode, John Chip Reed, R. Dennis Steed, Stephen W. Anderson, Leigh Steed, Diane Hopkins, Chun Xia, Jin-Xiong She

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent. Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay. Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean = 242 ng/ml) compared to patients without any complications (mean = 201 ng/ml) (p = 3.5×10 -6 ). Furthermore, mean serum MCP-1 is higher in controls (mean = 261 ng/ml) than T1D patients (mean = 208 ng/ml) (p<10 -23 ). More importantly, the frequency of subjects with extremely high levels (>99 th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio = 0.11, p<10 -33 ). Conclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.

Original languageEnglish (US)
Article numbere17822
JournalPloS one
Volume6
Issue number4
DOIs
StatePublished - Apr 21 2011

Fingerprint

insulin-dependent diabetes mellitus
Chemokine CCL2
Diabetes Complications
Medical problems
Type 1 Diabetes Mellitus
Chemokines
Ligands
Serum
Blood Proteins
gamma chemokines
ligands
chemokine CCL2
diabetic complications
Assays
glycohemoglobin
assays
Infiltration
Genetic Promoter Regions
odds ratio
Single Nucleotide Polymorphism

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Chemokine (c-c motif) ligand 2 (ccl2) in sera of patients with type 1 diabetes and diabetic complications. / Guan, Ruili; Purohit, Sharad B; Wang, Hongjie; Bode, Bruce; Reed, John Chip; Steed, R. Dennis; Anderson, Stephen W.; Steed, Leigh; Hopkins, Diane; Xia, Chun; She, Jin-Xiong.

In: PloS one, Vol. 6, No. 4, e17822, 21.04.2011.

Research output: Contribution to journalArticle

Guan, R, Purohit, SB, Wang, H, Bode, B, Reed, JC, Steed, RD, Anderson, SW, Steed, L, Hopkins, D, Xia, C & She, J-X 2011, 'Chemokine (c-c motif) ligand 2 (ccl2) in sera of patients with type 1 diabetes and diabetic complications', PloS one, vol. 6, no. 4, e17822. https://doi.org/10.1371/journal.pone.0017822
Guan, Ruili ; Purohit, Sharad B ; Wang, Hongjie ; Bode, Bruce ; Reed, John Chip ; Steed, R. Dennis ; Anderson, Stephen W. ; Steed, Leigh ; Hopkins, Diane ; Xia, Chun ; She, Jin-Xiong. / Chemokine (c-c motif) ligand 2 (ccl2) in sera of patients with type 1 diabetes and diabetic complications. In: PloS one. 2011 ; Vol. 6, No. 4.
@article{e2e5c5d993d44a299fe2c787aaaddd03,
title = "Chemokine (c-c motif) ligand 2 (ccl2) in sera of patients with type 1 diabetes and diabetic complications",
abstract = "Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent. Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay. Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean = 242 ng/ml) compared to patients without any complications (mean = 201 ng/ml) (p = 3.5×10 -6 ). Furthermore, mean serum MCP-1 is higher in controls (mean = 261 ng/ml) than T1D patients (mean = 208 ng/ml) (p<10 -23 ). More importantly, the frequency of subjects with extremely high levels (>99 th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio = 0.11, p<10 -33 ). Conclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.",
author = "Ruili Guan and Purohit, {Sharad B} and Hongjie Wang and Bruce Bode and Reed, {John Chip} and Steed, {R. Dennis} and Anderson, {Stephen W.} and Leigh Steed and Diane Hopkins and Chun Xia and Jin-Xiong She",
year = "2011",
month = "4",
day = "21",
doi = "10.1371/journal.pone.0017822",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Chemokine (c-c motif) ligand 2 (ccl2) in sera of patients with type 1 diabetes and diabetic complications

AU - Guan, Ruili

AU - Purohit, Sharad B

AU - Wang, Hongjie

AU - Bode, Bruce

AU - Reed, John Chip

AU - Steed, R. Dennis

AU - Anderson, Stephen W.

AU - Steed, Leigh

AU - Hopkins, Diane

AU - Xia, Chun

AU - She, Jin-Xiong

PY - 2011/4/21

Y1 - 2011/4/21

N2 - Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent. Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay. Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean = 242 ng/ml) compared to patients without any complications (mean = 201 ng/ml) (p = 3.5×10 -6 ). Furthermore, mean serum MCP-1 is higher in controls (mean = 261 ng/ml) than T1D patients (mean = 208 ng/ml) (p<10 -23 ). More importantly, the frequency of subjects with extremely high levels (>99 th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio = 0.11, p<10 -33 ). Conclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.

AB - Background: Chemokine (C-C motif) ligand 2 (CCL2), commonly known as monocyte chemoattractant protein-1 (MCP-1), has been implicated in the pathogenesis of many diseases characterized by monocytic infiltration. However, limited data have been reported on MCP-1 in type 1 diabetes (T1D) and the findings are inconclusive and inconsistent. Methods: In this study, MCP-1 was measured in the sera from 2,472 T1D patients and 2,654 healthy controls using a Luminex assay. The rs1024611 SNP in the promoter region of MCP-1 was genotyped for a subset of subjects (1764 T1D patients and 1323 controls) using the TaqMan-assay. Results: Subject age, sex or genotypes of MCP-1 rs1024611SNP did not have a major impact on serum MCP-1 levels in either healthy controls or patients. While hemoglobin A1c levels did not have a major influence on serum MCP-1 levels, the mean serum MCP-1 levels are significantly higher in patients with multiple complications (mean = 242 ng/ml) compared to patients without any complications (mean = 201 ng/ml) (p = 3.5×10 -6 ). Furthermore, mean serum MCP-1 is higher in controls (mean = 261 ng/ml) than T1D patients (mean = 208 ng/ml) (p<10 -23 ). More importantly, the frequency of subjects with extremely high levels (>99 th percentile of patients or 955 ng/ml) of serum MCP-1 is significantly lower in the T1D group compared to the control group (odds ratio = 0.11, p<10 -33 ). Conclusion: MCP-1 may have a dual role in T1D and its complications. While very high levels of serum MCP-1 may be protective against the development of T1D, complications are associated with higher serum MCP-1 levels within the T1D group.

UR - http://www.scopus.com/inward/record.url?scp=79954521692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954521692&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0017822

DO - 10.1371/journal.pone.0017822

M3 - Article

C2 - 21532752

AN - SCOPUS:79954521692

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e17822

ER -